Molecular Pharmacology (USA) Limited (OTC BB: MLPH) announced today the filing of a new patent, Tissue Disruption Treatment and Composition for Use (US Patent number 11218382). The patent describes a proprietary process for the manufacture of topical biological secondary injury mediators (B-SIMs) that should have local, rather than systemic, effects and may be significantly less expensive to manufacture than conventional B-SIMs. MPL is developing its B-SIMs to stop the tissue disruption that occurs after injury by suppressing the body’s reactions, such as inflammation and damage/death of otherwise uninjured cells that are triggered in response to primary injury.
